UK markets closed

Newron Pharmaceuticals S.p.A. (NWPHF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.10000.0000 (0.00%)
At close: 02:18PM EST

Newron Pharmaceuticals S.p.A.

Via Antonio Meucci 3
Bresso, MI 20091
Italy
39 026 103461
https://www.newron.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees23

Key executives

NameTitlePayExercisedYear born
Mr. Stefan WeberCEO & Exec. Director459.83kN/A1965
Mr. Roberto GalliVP of Fin.N/AN/AN/A
Mr. Marco CaremiExec. VP of Bus. Devel.N/AN/A1957
Dr. Ravi AnandChief Medical Officer1.17MN/A1957
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Corporate governance

Newron Pharmaceuticals S.p.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.